Semax
Heptapeptide ACTH(4-10) Analog (Met-Glu-His-Phe-Pro-Gly-Pro)
Pre-Clinical Overview
Semax is a synthetic regulatory heptapeptide structurally derived from an adrenocorticotropic hormone fragment (ACTH 4-10) stabilized with a C-terminal Pro-Gly-Pro tripeptide. Examined in neuropharmacology laboratories for its modulation of BDNF, trkB receptors, and cerebral monoamines.
Verified UK Suppliers for Semax
| Supplier | Assay Purity | Reagent Format | Dispatch Location | Notes | Access |
|---|---|---|---|---|---|
| PharmaGrade Store | ≥99.1% (HPLC) | spray | United Kingdom (Royal Mail 24) | High-purity lyophilized vials and calibrated laboratory nasal atomizers. | |
| Direct Peptides | ≥99.0% (HPLC) | vial | UK Hub & Europe | Standardized research vials verified across dual-wavelength UV chromatograms. | |
| Direct Sarms | ≥98.6% (HPLC) | spray | United Kingdom Express | Laboratory liquid and powder reagent formats with analytical COA documentation. | |
| Peptide Works | ≥98.9% (HPLC) | vial | Manchester UK Hub | Solid-phase peptide synthesized vials dispatched with digital purity certificate. | |
| PharmaLab Global | ≥99.3% (HPLC) | spray | London UK Hub | High-throughput assayed vials and metered laboratory nasal spray units. |
Molecular Signaling Pathways
- 1Upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA transcription in hippocampal neurons.
- 2Enhances tyrosine kinase receptor B (trkB) phosphorylation, facilitating synaptic plasticity and dendritic arborization.
- 3Modulates dopamine and serotonin metabolic turnover in prefrontal cortical tissue slices.
- 4Provides neuroprotective ischemic mitigation by suppressing inducible nitric oxide synthase and caspase-3 cascades.
Laboratory Evaluation Guidelines
Available as lyophilized powder or metered intranasal aqueous formulation. Demonstrates high enzymatic stability against carboxypeptidases owing to the C-terminal Pro-Gly-Pro motif.
Receptor Affinity, SPPS Synthesis & Pharmacokinetics
Standardized chemical parameters, solid-phase synthesis criteria, and quantitative receptor affinity benchmarks for Semax.
- BDNF/TrkB axis transcriptional upregulation
- Pyramidal neuron CA1 preservation under ischemic occlusion
- Attenuation of lipid peroxidation and superoxide radical damage
Documented Biochemical Endpoints & Statistical Significance
| Study Design | Cohort (n) | Measured Biological Endpoint | Statistical Significance | NCBI Citation |
|---|---|---|---|---|
| In Vitro Assay | n = 30 glial and neuronal cultures | Quantification of BDNF and trkB mRNA expression | p < 0.001 vs baseline | PMID 16787421 |
| Preclinical In Vivo | n = 48 carotid occlusion rodent models | Preservation of CA1 hippocampal pyramidal neuron density | p < 0.01 vs ischemia group | PMID 9444747 |
Indexed Scientific Literature
Curated Scientific Q&A for Semax
Authoritative pre-clinical, analytical, and statutory handling guidelines for laboratory researchers.
Semax (Heptapeptide ACTH(4-10) Analog (Met-Glu-His-Phe-Pro-Gly-Pro)) is indexed in the CAS Registry under #80714-61-0. Its empirical molecular formula is C37H51N9O10S with a monoisotopic molecular weight of 813.92 g/mol. It is cataloged under the Neuropeptides & CNS Signaling research classification.
More Reagents in Neuropeptides & CNS Signaling
Selank
Synthetic Tuftsin Heptapeptide Analogue (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
Selank is a synthetic regulatory heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, extended with a C-terminal Pro-Gly-Pro tripeptide. Examined in neuroimmunology laboratories for its allosteric modulation of GABAA receptors, enkephalinase inhibition, and IL-6 expression.